Form 10-Q Beam Therapeutics Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
JPMorgan Reiterates Overweight Rating on Beam Therapeutics Inc (BEAM)
November 5, 2024 2:56 PM ESTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $48.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).
The analyst comments "Key updates alongside 3Q results (loss per share of $1.17) centered on the companys SCD/B-thal cell therapy franchise ahead of multiple presentations at... More
Stifel Defending Beam Therapeutics Inc (BEAM): 'Reactions To Initial BEAM-101 Update Strikes Us As Overreaction'
November 5, 2024 11:47 AM ESTStifel analyst Benjamin Burnett reiterated a Buy rating and $69.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM)
The analyst comments "As expected from an initial update from a lead program, early BEAM-101 (sickle cell disease [SCD]) disclosure offers important takeaways that, understandably, trigger investor... More
